Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness

Ahmed et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.191
Dec 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Unresolved symptoms 85% primary Improvement Relative Risk Unresolved symptoms (b) 63% Viral clearance 76% Viral clearance (b) 57% Viral clearance (c) 63% Viral clearance (d) 41% Time to viral- 24% Time to viral- (b) 9% Hospitalization time 1% no CI Hospitalization time (b) -4% no CI Ivermectin  Ahmed et al.  EARLY TREATMENT  DB RCT Is early treatment with ivermectin beneficial for COVID-19? Double-blind RCT 72 patients in Bangladesh Improved viral clearance with ivermectin (p=0.03) c19ivm.org Ahmed et al., Int. J. Infectious Disea.., Dec 2020 Favorsivermectin Favorscontrol 0 0.5 1 1.5 2+
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020, now with p < 0.00000000001 from 105 studies, recognized in 23 countries.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 110 treatments. c19ivm.org
Small 72 patient RCT of ivermectin and ivermectin + doxycycline showing faster recovery with ivermectin. The ivermectin + doxycycline group uses only a single dose of ivermectin vs. 5 daily doses for the ivermectin group. PCR testing was only done weekly after day 7, therefore hospitalization time may not match symptomatic recovery.
Ivermectin group: 12mg daily for 5 days
Ivermectin + doxycycline: 12mg ivermectin single dose, 200mg doxycycline + 100mg bid 4 days
This is the 8th of 52 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000021.
This is the 24th of 105 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 774 quintillion).
risk of unresolved symptoms, 85.0% lower, RR 0.15, p = 0.09, treatment 0 of 17 (0.0%), control 3 of 19 (15.8%), NNT 6.3, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 7, fever, ivermectin (5 days), primary outcome.
risk of unresolved symptoms, 62.7% lower, RR 0.37, p = 0.35, treatment 1 of 17 (5.9%), control 3 of 19 (15.8%), NNT 10, day 7, fever, ivermectin (1 day) + doxycycline.
risk of no viral clearance, 75.6% lower, HR 0.24, p = 0.03, treatment 11 of 22 (50.0%), control 20 of 23 (87.0%), NNT 2.7, adjusted per study, inverted to make HR<1 favor treatment, day 7, ivermectin (5 days).
risk of no viral clearance, 56.5% lower, HR 0.43, p = 0.22, treatment 16 of 23 (69.6%), control 20 of 23 (87.0%), NNT 5.8, adjusted per study, inverted to make HR<1 favor treatment, day 7, ivermectin (1 day) + doxycycline.
risk of no viral clearance, 63.0% lower, HR 0.37, p = 0.02, treatment 5 of 22 (22.7%), control 14 of 23 (60.9%), NNT 2.6, adjusted per study, inverted to make HR<1 favor treatment, day 14, ivermectin (5 days).
risk of no viral clearance, 41.2% lower, HR 0.59, p = 0.19, treatment 9 of 23 (39.1%), control 14 of 23 (60.9%), NNT 4.6, adjusted per study, inverted to make HR<1 favor treatment, day 14, ivermectin (1 day) + doxycycline.
time to viral-, 23.6% lower, relative time 0.76, p = 0.02, treatment 22, control 23, ivermectin (5 days).
time to viral-, 9.4% lower, relative time 0.91, p = 0.27, treatment 23, control 23, ivermectin (1 day) + doxycycline.
hospitalization time, 1.0% lower, relative time 0.99, treatment 22, control 23, ivermectin, PCR testing only done weekly after day 7.
hospitalization time, 4.1% higher, relative time 1.04, treatment 23, control 23, ivermectin + doxycycline, PCR testing only done weekly after day 7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ahmed et al., 2 Dec 2020, Double Blind Randomized Controlled Trial, Bangladesh, peer-reviewed, mean age 42.0, 15 authors, average treatment delay 3.83 days, dosage 12mg days 1-5, the ivermectin + doxycycline group took only a single dose of ivermectin.
This PaperIvermectinAll
A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness
Sabeena Ahmed, Mohammad Mahbubul Karim, Allen G Ross, Mohammad Sharif Hossain, John D Clemens, Mariya Kibtiya Sumiya, Ching Swe Phru, Mustafizur Rahman, Khalequ Zaman, Jyoti Somani, Rubina Yasmin, Mohammad Abul Hasnat, Ahmedul Kabir, Asma Binte Aziz, Wasif Ali Khan
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.191
Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. A randomized, double-blind, placebo-controlled trial was conducted to determine the rapidity of viral clearance and safety of ivermectin among adult SARS-CoV-2 patients. The trial included 72 hospitalized patients in Dhaka, Bangladesh, who were assigned to one of three groups: oral ivermectin alone (12 mg once daily for 5 days), oral ivermectin in combination with doxycycline (12 mg ivermectin single dose and 200 mg doxycycline on day 1, followed by 100 mg every 12 h for the next 4 days), and a placebo control group. Clinical symptoms of fever, cough, and sore throat were comparable among the three groups. Virological clearance was earlier in the 5-day ivermectin treatment arm when compared to the placebo group (9.7 days vs 12.7 days; p = 0.02), but this was not the case for the ivermectin + doxycycline arm (11.5 days; p = 0.27). There were no severe adverse drug events recorded in the study. A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19. Larger trials will be needed to confirm these preliminary findings.
Ethical review The trial was approved by the Institutional Review Board (Research Review Committee and Ethical Review Committee) of icddr,b and subsequently by the National Ethics Review Committee of Bangladesh Medical Research Council and Clinical Trial Advisory Committee of the Directorate General of Drug Administration, Government of Bangladesh. Written informed consent was obtained from all patients. Declaration of interests The authors declare that there are no known competing financial interests or personal relationships that could have appeared to influence the work described in this paper. Conflicts of interest The authors have no conflicts of interest to declare. Author agreement All authors have seen and approved the final version of the manuscript being submitted. The article is the authors' original work, has not received prior publication, and is not under consideration for publication elsewhere.
References
Alam, Murshed, Bhiuyan, Saber, Alam, A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline, J Bangladesh Coll Physic Surg, doi:10.3329/jbcps.v38i0.47512
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro Antiviral Res
Chiu, Lu, Metabolism and tissue residues
Lespine, Alvinerie, Sutra, Pors, Chartier, Influence of the route of administration on efficacy and tissue distribution of ivermectin in goat, Vet Parasitol
Rajter, Sherman, Fatteh, Vogel, Sacks et al., ICON (Ivermectin in COvid Nineteen) study: use of ivermectin is associated with lower mortality in hospitalised patients with COVID-19, medRxiv
Wu, Liu, Yang, Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharm Sin B, doi:10.1016/j.apsb.2020.02.008
{ 'indexed': {'date-parts': [[2024, 4, 8]], 'date-time': '2024-04-08T17:18:13Z', 'timestamp': 1712596693038}, 'reference-count': 8, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2021, 2, 1]], 'date-time': '2021-02-01T00:00:00Z', 'timestamp': 1612137600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2020, 11, 26]], 'date-time': '2020-11-26T00:00:00Z', 'timestamp': 1606348800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'funder': [{'name': 'eximco Pharmaceutical Limited (BPL), Bangladesh.'}], 'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.com', 'ijidonline.com', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2021, 2]]}, 'DOI': '10.1016/j.ijid.2020.11.191', 'type': 'journal-article', 'created': {'date-parts': [[2020, 12, 2]], 'date-time': '2020-12-02T17:03:02Z', 'timestamp': 1606928582000}, 'page': '214-216', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 162, 'title': 'A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness', 'prefix': '10.1016', 'volume': '103', 'author': [ {'given': 'Sabeena', 'family': 'Ahmed', 'sequence': 'first', 'affiliation': []}, {'given': 'Mohammad Mahbubul', 'family': 'Karim', 'sequence': 'additional', 'affiliation': []}, {'given': 'Allen G.', 'family': 'Ross', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohammad Sharif', 'family': 'Hossain', 'sequence': 'additional', 'affiliation': []}, {'given': 'John D.', 'family': 'Clemens', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mariya Kibtiya', 'family': 'Sumiya', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ching Swe', 'family': 'Phru', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mustafizur', 'family': 'Rahman', 'sequence': 'additional', 'affiliation': []}, {'given': 'Khalequ', 'family': 'Zaman', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jyoti', 'family': 'Somani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rubina', 'family': 'Yasmin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohammad Abul', 'family': 'Hasnat', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ahmedul', 'family': 'Kabir', 'sequence': 'additional', 'affiliation': []}, {'given': 'Asma Binte', 'family': 'Aziz', 'sequence': 'additional', 'affiliation': []}, {'given': 'Wasif Ali', 'family': 'Khan', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.ijid.2020.11.191_bib0005', 'doi-asserted-by': 'crossref', 'first-page': '10', 'DOI': '10.3329/jbcps.v38i0.47512', 'article-title': 'A Case Series of 100 COVID-19 Positive Patients Treated with ' 'Combination of Ivermectin and Doxycycline', 'volume': '38', 'author': 'Alam', 'year': '2020', 'journal-title': 'J Bangladesh Coll Physic Surg'}, { 'key': '10.1016/j.ijid.2020.11.191_bib0010', 'series-title': '"The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 ' 'in vitro', 'author': 'Caly', 'year': '2020'}, { 'key': '10.1016/j.ijid.2020.11.191_bib0015', 'series-title': 'Interim Clinical Guidance for Management of Patients with Confirmed 2019 ' 'Novel Coronavirus (2019-nCoV) Infection, Updated March 7, 2020', 'author': 'Centers for Disease Control and Prevention', 'year': '2020'}, { 'key': '10.1016/j.ijid.2020.11.191_bib0020', 'series-title': 'Ivermectin and Abamectin', 'first-page': '131', 'article-title': 'Metabolism and tissue residues', 'author': 'Chiu', 'year': '1989'}, { 'key': '10.1016/j.ijid.2020.11.191_bib0025', 'series-title': 'COVID-19 Dashboard by the Center for Systems Science and Engineering ' '(CSSE) at Johns Hopkins University', 'author': 'Johns Hopkins University of Medicine COVID-19', 'year': '2020'}, { 'key': '10.1016/j.ijid.2020.11.191_bib0030', 'doi-asserted-by': 'crossref', 'first-page': '251', 'DOI': '10.1016/j.vetpar.2004.11.028', 'article-title': 'Influence of the route of administration on efficacy and tissue ' 'distribution of ivermectin in goat', 'volume': '128', 'author': 'Lespine', 'year': '2005', 'journal-title': 'Vet Parasitol'}, { 'key': '10.1016/j.ijid.2020.11.191_bib0035', 'article-title': 'ICON (Ivermectin in COvid Nineteen) study: use of ivermectin is ' 'associated with lower mortality in hospitalised patients with COVID-19', 'volume': '2020', 'author': 'Rajter', 'year': '2020', 'journal-title': 'medRxiv'}, { 'key': '10.1016/j.ijid.2020.11.191_bib0040', 'article-title': 'Analysis of therapeutic targets for SARS-CoV-2 and discovery of ' 'potential drugs by computational methods', 'author': 'Wu', 'year': '2020', 'journal-title': 'Acta Pharm Sin B'}], 'container-title': 'International Journal of Infectious Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1201971220325066?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1201971220325066?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2023, 6, 30]], 'date-time': '2023-06-30T15:49:31Z', 'timestamp': 1688140171000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1201971220325066'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 2]]}, 'references-count': 8, 'alternative-id': ['S1201971220325066'], 'URL': 'http://dx.doi.org/10.1016/j.ijid.2020.11.191', 'relation': {}, 'ISSN': ['1201-9712'], 'subject': ['Infectious Diseases', 'Microbiology (medical)', 'General Medicine'], 'container-title-short': 'International Journal of Infectious Diseases', 'published': {'date-parts': [[2021, 2]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'A five-day course of ivermectin for the treatment of COVID-19 may reduce the ' 'duration of illness', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'International Journal of Infectious Diseases', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.ijid.2020.11.191', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2020 The Authors. Published by Elsevier Ltd on behalf of International ' 'Society for Infectious Diseases.', 'name': 'copyright', 'label': 'Copyright'}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit